Sangamo Therapeutics News

US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results

Yahoo FinanceMay 12 09:17 ET

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 12 08:28 ET

Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive Into Financials and Strategic Highlights

Yahoo FinanceMay 10 15:58 ET

Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript

Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 19:13 ET

Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 325 percent decrease over earnings

BenzingaMay 9 16:30 ET

Sangamo Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 16:10 ET · Announcements

Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000

04:03 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000

MT NewswiresMay 9 16:03 ET

Express News | Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

ReutersMay 9 16:01 ET

Express News | Sangamo Therapeutics Q1 Revenue USD 481 Thousand Vs. Ibes Estimate USD 6.65 Million

ReutersMay 9 16:01 ET

Express News | Sangamo Therapeutics Q1 Operating Expenses USD 52 Million

ReutersMay 9 16:01 ET

Express News | Sangamo Therapeutics Q1 Operating Income USD -51.526 Million

ReutersMay 9 16:01 ET

Express News | Sangamo Therapeutics Q1 Net Income USD -49.089 Million

ReutersMay 9 16:01 ET

Sangamo Therapeutics 1Q Rev $481,000 >SGMO

Sangamo Therapeutics 1Q Rev $481,000 >SGMO

Dow JonesMay 9 16:01 ET

Express News | Sangamo Therapeutics Presents Modular Integrase Technology Engineered To Enable Large-Scale Genome Editing

BenzingaMay 9 08:45 ET

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

BusinesswireMay 9 08:05 ET

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9,

BusinesswireMay 2 16:15 ET

Express News | Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting

Moomoo 24/7Apr 22 16:36 ET

Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?

Seeking AlphaApr 2 11:36 ET

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review 2024, Featuring Takeda Pharmaceutical, JCR Pharmaceuticals, GC Corp, RegenxBio, Sangamo Therapeutics and Generium

Yahoo FinanceApr 2 09:48 ET

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

Yahoo FinanceMar 25 14:52 ET